India, May 8 -- The U.S. Food and Drug Administration has announced plans to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products for American consumers and patients.
This move builds upon the agency's Office of Inspection and Investigations Foreign Unannounced Inspection Pilot program in India and China and aims to ensure that foreign companies will receive the same level of regulatory oversight and scrutiny as domestic companies, FDA said in a press release.
"For too long, foreign companies have enjoyed a double standard-given advanced notice before facility inspections, while American manufacturers are held to rigorous standards with no such wa...